Intuitive Surgical, Inc.'s Stock Analysis

Intuitive Announces CEO Transition Effective July 2025

Intuitive Surgical has announced that Dave Rosa, currently the President, will be promoted to Chief Executive Officer effective July 1, 2025. This transition will see current CEO Gary Guthart take on the role of executive chair of the board, while Craig Barratt, the current Board Chair, will become the lead independent director. Guthart will assist Rosa during the transition and continue to advise the company in a senior capacity.

Dave Rosa has been with Intuitive for nearly 30 years, holding various leadership roles that include engineering, product development, and strategic growth. His experience includes founding key groups within the company and overseeing the development of significant products such as the da Vinci SP robotic-assisted surgical system. The company is marking its 30th year in robotic-assisted technology, emphasizing its commitment to improving patient outcomes and expanding access to minimally invasive care.

May 15, 2025 09:05:20

Intuitive Reports 19% Revenue Growth in Q1 2025 Earnings

Intuitive Surgical announced its financial results for the first quarter of 2025, reporting a revenue of $2.25 billion, which represents a 19% increase compared to $1.89 billion in the same quarter of 2024. The growth was attributed to a rise in da Vinci procedures, higher placements of da Vinci surgical systems, and an expanded installed base, which reached 10,189 systems, up 15% from the previous year. The company placed 367 da Vinci systems during the quarter, significantly up from 313 in Q1 2024, with a notable increase in the placement of da Vinci 5 systems from 8 to 147 units year-over-year.

GAAP net income for the first quarter was $698 million, or $1.92 per diluted share, compared to $545 million, or $1.51 per diluted share, in the first quarter of 2024. Non-GAAP net income was reported at $662 million, or $1.81 per diluted share, also showing an increase from $541 million, or $1.50 per diluted share, in the prior year. The company ended the quarter with $9.10 billion in cash and investments, reflecting a $269 million increase, primarily due to cash generated from operations.

Apr 22, 2025 16:03:30

Intuitive Reports $2.41 Billion Revenue in Q4 2024

Intuitive announced a revenue increase of 25% in the fourth quarter of 2024, reaching $2.41 billion compared to $1.93 billion in the same period last year. The company also experienced an 18% growth in worldwide da Vinci procedures and placed 493 da Vinci surgical systems, raising its installed base to 9,902 systems, a 15% increase from the previous year. Additionally, the GAAP net income attributable to Intuitive was $686 million, or $1.88 per diluted share, up from $606 million, or $1.69 per diluted share, in Q4 2023, indicating an overall positive financial performance for the quarter.

On the downside, the company reported an increase in expenses, including a $45 million contribution to the Intuitive Foundation, compared to $40 million in Q4 2023. Furthermore, the fourth quarter 2024 GAAP income from operations was impacted by share-based compensation expenses amounting to $180 million, which rose from $152 million in the prior year. The report also noted that the 2025 financial outlook anticipates slower growth in worldwide da Vinci procedures, projected at 13% to 16%, compared to 17% growth in 2024.

Jan 23, 2025 16:03:01

Intuitive Reports $2.41 Billion Revenue for Q4 2024

Intuitive announced a preliminary revenue of approximately $2.41 billion for the fourth quarter of 2024, reflecting a 25% increase from $1.93 billion in the same quarter of 2023. The company also reported a full-year revenue of approximately $8.35 billion, up 17% from $7.12 billion in 2023. Additionally, worldwide da Vinci procedures grew by about 18% in Q4 2024, and the company placed 493 da Vinci surgical systems during the quarter, marking a 19% increase compared to the previous year.

On the downside, the company incurred increased expenses, including a $45 million contribution to the Intuitive Foundation, which was higher than the $40 million contribution in Q4 2023. While the company did not experience significant disruptions due to COVID-19, it noted that some prior year impacts were felt, particularly in early 2023. The preliminary results are subject to adjustments based on final audits, indicating that the reported figures may change.

Jan 15, 2025 09:00:19

Intuitive Reports Strong Q3 Growth and Earnings Increase

Intuitive Surgical announced impressive third-quarter results, showcasing an 18% growth in worldwide da Vinci procedures compared to the previous year. The company reported a revenue increase to $2.04 billion, a 17% rise from $1.74 billion in Q3 2023. Notably, their net income also saw a significant increase, reaching $565 million, or $1.56 per diluted share, up from $416 million, or $1.16 per diluted share, last year. The positive momentum is further supported by the successful placement of 379 da Vinci surgical systems, marking a substantial growth in their installed base.

On the downside, the company faced challenges related to share-based compensation expenses, which increased to $176 million from $157 million year-over-year. Despite this, Intuitive's overall financial health remains strong, ending the quarter with $8.31 billion in cash and investments, reflecting a $628 million increase driven by operational cash flow. The CEO expressed satisfaction with the adoption of their latest surgical system, indicating a commitment to enhancing patient outcomes amidst a competitive landscape.

Oct 17, 2024 16:02:35

David J. Rosa Joins Intuitive Board of Directors

Intuitive has appointed David J. Rosa, the company's president, to its Board of Directors, enhancing leadership with his extensive experience in operations and innovation. This move is seen as positive for the company's strategic direction and governance. Rosa's background includes over 27 years at Intuitive, contributing to various functions, and he holds multiple patents. The Board has expanded from eleven to twelve members, indicating growth and a commitment to effective oversight.

Jul 25, 2024 09:00:42

Intuitive Reports Strong Q2 Earnings Growth in Robotic Surgery Sector

Intuitive, a leader in robotic-assisted surgery, saw a 17% increase in da Vinci procedures and placed 341 da Vinci surgical systems, contributing to a 14% revenue growth in Q2 2024. The company's GAAP net income rose to $527 million, while non-GAAP net income reached $641 million. Intuitive ended the quarter with $7.68 billion in cash. Despite previous COVID-19 impacts, the company experienced no disruptions in procedure volumes in the first half of 2024. CEO Gary Guthart expressed satisfaction with the quarter's performance and emphasized the focus on improving patient outcomes.

Jul 18, 2024 16:03:15

Intuitive Receives FDA Clearance for Fifth-Generation Robotic System

Intuitive Surgical announces FDA clearance for da Vinci 5, a next-gen robotic system with improved accuracy, force-sensing technology, enhanced computing power, and greater surgeon comfort. The system aims to enhance patient outcomes, streamline workflow, and potentially save time. Initial launch to a limited U.S. customer base before broader introduction globally. Company emphasizes continuous innovation and integration of new features based on customer needs and feedback.

Mar 14, 2024 16:32:49

Intuitive Announces Strong Q4 2023 Earnings

Intuitive reported strong Q4 2023 earnings with a 17% increase in revenue, driven by a 21% growth in da Vinci procedure volume and an increase in installed systems. The company placed 415 da Vinci surgical systems and grew its installed base to 8,606 systems. GAAP net income increased to $606 million, and non-GAAP net income was $574 million. The company obtained CE mark certification for the da Vinci single-port surgical system and plans to commercialize it in select European countries in 2024.

Jan 23, 2024 16:02:26

Intuitive Announces Positive Fourth Quarter and Full Year 2023 Results

Intuitive reported strong growth in da Vinci procedures and system placements in the fourth quarter and full year 2023. Preliminary revenue for the fourth quarter and full year 2023 showed significant increases. While COVID-19 had some negative impact on procedure volumes in early 2023, the company did not experience significant disruptions later in the year. The CEO expressed satisfaction with customer adoption of their platforms and support for customers' acute interventions.

Jan 09, 2024 16:03:40